Identification of Aggression-Biosignatures in psychiatric disorders

Identification of Aggression-Biosignatures in psychiatric disorders - Q01

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035731

Enrollment

1100

Registered

2025-02-20

Start date

2025-03-10

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with substance use disorders, psychotic disorders, affective disorders, anxiety disorders, acute anorexia nervosa, PTSD, ASPD, BPD, CD, ODD, ADHD, ASD with and without elevated aggressive behavior at study intake. F10-F19 F20-F29 F30-F39 F40-F48 F50-F59 F60-F69 F90-F98 F99

Interventions

Group 1: Patients suffering from all kinds of mental disorders according to DSM-5/ICD-10/ICD-11 except dementias, i.e. including substance use disorders, psychotic disorders, affective disorders, anxi

Eligibility

Sex/Gender

All

Age

10 Years to 40 Years

Inclusion criteria

Inclusion criteria: Written informed consent by participant or legal guardian (parents). Ability to understand the study procedures and to provide consent/assent. For patients, any mental disorder according to DSM-5 / ICD-10 / ICD-11; in particular, are included in the study substance use disorders, psychotic disorders, affective disorders, anxiety disorders, acute anorexia nervosa, PTSD, ASPD, BPD, CD, ODD, ADHD, ASD with and without elevated aggressive behavior at study intake.

Exclusion criteria

Exclusion criteria: Dementia. Severe mental retardation (IQ<50). Insufficient ability to read and write German (adults / parents or caregivers). Inability to comply with the study protocol. Severe somatic or neurological disorders that affect the central nervous system or hormonal functions (such as encephalitis, brain and hormone secreting tumors, dementia, epilepsy, fetal alcohol syndrome). Presence of MRI contraindications. For healthy controls, any mental disorder according to DSM-5 / ICD-10 / ICD-11.

Design outcomes

Primary

Measure	Time frame
To provide transdiagnostic characterization of aggression in mental disorders (AMD), including the assessment of dysfunctions in cognitive control (CS) and threat/potential harm and frustrative non-reward (NVS), by using standardized multilevel measurements of behavioral and biological systems, i.e., MR imaging, genetic, and hormonal data as well as neuropsychological and psychopathological assessment.	—

Measure

Time frame

To provide transdiagnostic characterization of aggression in mental disorders (AMD), including the assessment of dysfunctions in cognitive control (CS) and threat/potential harm and frustrative non-reward (NVS), by using standardized multilevel measurements of behavioral and biological systems, i.e., MR imaging, genetic, and hormonal data as well as neuropsychological and psychopathological assessment.

—

Secondary

Measure	Time frame
To examine shared and disorder-specific mechanisms of aggressive behavior and their neurobiological correlates.	—

Countries

Germany

Contacts

Public ContactUte Habel

University Hospital RWTH Aachen

uhabel@ukaachen.de+49 241 80-80368

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026